Shane Salter

Mr. Shane Salter


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CHCarrie Hoppes
Carrie Hoppes
HRHolly Richard
Holly Richard
SSShane Salter
Shane Salter
AVAndrew Vetter
Andrew Vetter
PHPearson Van Horn
Pearson Van Horn
PHPedram Hovareshti
Pedram Hovareshti
While most individuals recover from mild traumatic brain injury (mTBI) within 3 months, 10–20% continue to experience chronic post-concussive symptoms such as headaches, dizziness, and imbalance. These individuals may benefit from vestibular rehabilitation, but military medicine needs a device that can standardize key elements of vestibular rehabilitation while allowing customization and targeting military-relevant tasks. We designed RehabXR, a portable mixed-reality-based platform for assessment and rehabilitation of multisensory and cognitive impairments after mTBI. RehabXR includes a virtual reality headset, controller, custom 3D-printed replica M4 rifle, and three first-person shooter games targeting common impairments post-mTBI. To assess usability, facilitated group discussions were conducted with ten military clinicians with post-mTBI rehabilitation experience and ten individuals with a history of mTBI. Clinicians and individuals with a history of mTBI rated RehabXR prototype usability favorably, with average System Usability Scale scores of 84.5 (range 55.0–97.5) and 85.2 (range 77.5–95.0), respectively. Clinicians liked the realism, engagement, interactivity, applicability, portability, and transparency (availability of quantitative outcome metrics). Individuals with a history of mTBI liked the ease of use and reported the games were realistic, fun, and engaging. After four weeks of use, patients rated RehabXR usability favorably (although somewhat lower than the prototype) with an average System Usability Scale score of 70.89 (range 55.0–87.5). These findings support RehabXR’s feasibility and acceptability and provide a foundation for studies of clinical effectiveness and return-to-duty applications.